c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma
about
Biomarker development in MET-targeted therapyLigand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligandsTumor stroma as targets for cancer therapyOckham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerPrognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literaturesc-MET protects breast cancer cells from apoptosis induced by sodium butyrate.Role of myofibroblasts at the invasion front.The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical AspectsImmunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluationIncreased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsOxidative stress promotes myofibroblast differentiation and tumour spreading.Upregulated expression of Ezrin and invasive phenotype in malignantly transformed esophageal epithelial cellsIntegrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cellsM10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo.c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapyHepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.Biomarkers in lung cancer: from early detection to novel therapeutics and decision makingCarcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression.Overexpression of c-Met and CD44v6 receptors contributes to autocrine TGF-β1 signaling in interstitial lung diseasec-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.c-MET as a potential therapeutic target and biomarker in cancer.Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells.Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line.A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway.Basement membrane matrix modifies cytokine interactions between lung cancer cells and fibroblasts.Different roles of myofibroblasts in the tumorigenesis of nonsmall cell lung cancer.Angiogenesis and extracellular matrix remodelling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non-mucinous tumours.Autocrine activation of the hepatocyte growth factor receptor/met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion.SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma.The signaling adapter protein PINCH is up-regulated in the stroma of common cancers, notably at invasive edges.Survival prediction of stage I lung adenocarcinomas by expression of 10 genesMicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy.Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis.EGFR-TKIs resistance via EGFR-independent signaling pathways.
P2860
Q26751332-96069F20-4B96-4A73-8A64-839545DCEACDQ26829104-3E220D00-5212-45D1-85FA-072150B26056Q27015980-F40151AF-3CC8-4F1A-9CF9-CCB25F4FDC97Q28067777-48CA4DDD-206E-438E-95A0-D54CB2680BC9Q33748638-AF430F0D-ADFE-418D-B6BD-C3DBD6981D98Q34131128-2AD62718-D53F-4F32-A4F6-41D8E66D64FDQ34584808-8DF88D17-B84F-459C-A4FA-B6D397214848Q35078950-BB2250C3-DB45-49EB-BE62-9F55B59CC10EQ35770249-004E2041-0D93-40EE-8199-614F0B3505E2Q35926926-2BECE758-6BDA-4F3F-85AE-35273B00BCE4Q36039273-9A53E81F-2DD2-4212-929D-6CBEF63EA6B1Q36179753-2B519F56-68AF-4870-9153-A9EF2299E982Q36323634-C8763B7B-FF9E-445E-A4F3-DE0A8BF15367Q36680112-514F4341-5DC8-4FAF-92D7-C62B181D23F7Q36731520-085DE9B7-6291-4771-9674-BF9E17CA5C84Q36828371-FFE35749-D9E3-4914-8B1E-2E14E96BF237Q37223558-098C2473-9DBE-4471-9CAD-1F62974A9721Q37342919-FFBB03DC-54A7-4FAB-B5E4-E616A8255C9DQ37621644-4ABD1987-B2DA-45C0-9F37-E11C6ACB2540Q37635850-0261D7BB-119B-4971-963D-A17F625CED7FQ37651008-AADA6148-E70F-43BC-A3BC-937759036069Q37730020-12DEE8E6-040A-4B32-9A3B-8F6CD6DDD2BBQ37962905-91195DCB-9022-458E-90C8-F16B63FBE85AQ38086460-94569975-B254-4BD2-ACAF-EFFC6F43C68EQ38241160-5BF8B8EA-DB3B-4756-96A9-12BBCA5DD879Q38481540-E24A2593-6958-4B0F-9752-5D4A5CBFF9B8Q39186173-A0A508FA-3FD4-44C7-B5FA-606B29243241Q39991720-BBCA4F50-BCD9-4137-A260-115B53325E6EQ40147314-22FA8E92-9F0B-4E08-8B63-D7AED5A90B92Q40336796-A37C4251-D1BA-4297-ADCC-E325CA6A55E8Q40414177-6F7C83FE-0976-4FF8-AACE-FFA1F1E637B8Q40529004-7B33C2D7-43AC-4784-ADA0-1D816DFA1D95Q40698534-E20CC157-6357-4F54-967C-35E0FAF7DD39Q40749632-F74C82E1-1666-4407-B4C1-573E4CE52B0EQ42525702-B1A406CC-C44E-449D-A8AC-A1DFF67FFD2DQ42585784-F3185BB8-11E1-40A9-A047-C3BB8D4CA0B1Q43184280-45E8CD1B-FF95-40C7-9419-4FC247337CD6Q44737495-EDA483FB-FAB4-41CA-9C95-33749CC9D7B4Q46920737-2EA53458-339A-48D3-A8F0-4C6575B8A0C0Q49887890-A26351FA-67AB-4542-8962-D84BDA35D71D
P2860
c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@ast
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@en
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@nl
type
label
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@ast
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@en
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@nl
prefLabel
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@ast
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@en
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@nl
P2093
P2860
P3181
P1476
c-MET expression in myofibrobl ...... ficance in lung adenocarcinoma
@en
P2093
S Hirohashi
P2860
P304
P3181
P356
10.1016/S0002-9440(10)64096-5
P407
P577
2001-04-01T00:00:00Z